Please wait





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person:  Includes (i) 2,300 American Depositary Shares ("Depositary Shares"), each representing thirty-five (35) Ordinary Shares, no par value per share ("Ordinary Shares") held by ADAR1 Partners, LP, (ii) 352 Depositary Shares held by Spearhead Insurance Solutions IDF, LLC, (iii) 349 Depositary Shares held by other separately managed accounts and (iv) 99,845 Depositary Shares underlying Warrants to Purchase Ordinary Shares Represented by American Depositary Shares or Exchange Warrants held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC as of March 31, 2026. Excludes 142,579 Depositary Shares underlying Warrants to Purchase Ordinary Shares Represented by American Depositary Shares or Exchange Warrants held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC, the exchange and exercise of which are subject to 4.99% beneficial ownership limitations determined in relation to the number of Ordinary Shares underlying the Depositary Shares. As the investment manager of ADAR1 Partners, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC and the separately managed accounts referenced above, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC and the separately managed accounts. Based on 1,961,206 Depositary Shares of Quoin Pharmaceuticals, Ltd. (the "Issuer") outstanding as of March 31, 2026, reported in the Issuer's Form 10-Q filed with the Securities and Exchange Commission on May 7, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person:  Includes (i) 2,300 American Depositary Shares ("Depositary Shares"), each representing thirty-five (35) Ordinary Shares, no par value per share ("Ordinary Shares") held by ADAR1 Partners, LP and (ii) 100,583 Depositary Shares underlying Warrants to Purchase Ordinary Shares Represented by American Depositary Shares or Exchange Warrants held by ADAR1 Partners, LP as of March 31, 2026. Excludes 109,113 Depositary Shares underlying Warrants to Purchase Ordinary Shares Represented by American Depositary Shares or Exchange Warrants held by ADAR1 Partners, LP, the exchange and exercise of which are subject to 4.99% beneficial ownership limitations determined in relation to the number of Ordinary Shares underlying the Depositary Shares. As the general partner of ADAR1 Partners, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP. Based on 1,961,206 Depositary Shares of Quoin Pharmaceuticals, Ltd. (the "Issuer") outstanding as of March 31, 2026, reported in the Issuer's Form 10-Q filed with the Securities and Exchange Commission on May 7, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person:  Includes (i) 2,300 American Depositary Shares ("Depositary Shares"), each representing thirty-five (35) Ordinary Shares, no par value per share ("Ordinary Shares") held by ADAR1 Partners, LP, (ii) 352 Depositary Shares held by Spearhead Insurance Solutions IDF, LLC, (iii) 349 Depositary Shares held by other separately managed accounts and (iv) 99,845 Depositary Shares underlying Warrants to Purchase Ordinary Shares Represented by American Depositary Shares or Exchange Warrants held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC as of March 31, 2026. Excludes 142,579 Depositary Shares underlying Warrants to Purchase Ordinary Shares Represented by American Depositary Shares or Exchange Warrants held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC, the exchange and exercise of which are subject to 4.99% beneficial ownership limitations determined in relation to the number of Ordinary Shares underlying the Depositary Shares. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC and the separately managed accounts. Based on 1,961,206 Depositary Shares of Quoin Pharmaceuticals, Ltd. (the "Issuer") outstanding as of March 31, 2026, reported in the Issuer's Form 10-Q filed with the Securities and Exchange Commission on May 7, 2026.


SCHEDULE 13G



 
ADAR1 Capital Management, LLC
 
Signature:/s/ Daniel Schneeberger
Name/Title:Daniel Schneeberger, Manager
Date:05/15/2026
 
ADAR1 Capital Management GP, LLC
 
Signature:/s/ Daniel Schneeberger
Name/Title:Daniel Schneeberger, Manager
Date:05/15/2026
 
Daniel Schneeberger
 
Signature:/s/ Daniel Schneeberger
Name/Title:Daniel Schneeberger, in his individual capacity
Date:05/15/2026